CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
-13.03%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$4.01B
AUM Growth
+$69M
(+1.8%)
Cap. Flow
+$681M
Cap. Flow
% of AUM
16.99%
Top 10 Holdings %
Top 10 Hldgs %
52.72%
Holding
62
New
7
Increased
9
Reduced
7
Closed
8
Top Buys
| 1 |
MaxCyte
MXCT
|
+$171M |
| 2 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$154M |
| 3 |
Absci
ABSI
|
+$89.8M |
| 4 |
Ginkgo Bioworks
DNA
|
+$83.5M |
| 5 |
Pacific Biosciences
PACB
|
+$76.4M |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$49.1M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$45.3M |
| 3 |
NeoGenomics
NEO
|
+$22.1M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$12.1M |
| 5 |
Clover Health Investments
CLOV
|
+$9.68M |
Sector Composition
| 1 | Healthcare | 91.34% |
| 2 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
1
DELISTED
Invitae Corporation
NVTA
| $347M | 8.64% |
12,203,669
| – | – |
|
2
BioLife Solutions
BLFS
$1.22B
| $320M | 7.97% |
7,566,292
+126,185
| +2% | +$5.34M |
|
3
Exact Sciences
EXAS
$10.2B
| $225M | 5.61% |
2,360,186
| – | – |
|
|
4
Pacific Biosciences
PACB
$351M
| $204M | 5.08% |
7,990,652
+2,990,652
| +60% | +$76.4M |
|
5
Fate Therapeutics
FATE
$111M
| $202M | 5.02% |
3,400,000
| – | – |
|
6
Alnylam Pharmaceuticals
ALNY
$61.1B
| $189M | 4.7% |
1,000,000
| – | – |
|
|
7
MaxCyte
MXCT
$155M
| $171M | 4.25% |
+13,971,334
| New | +$171M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $159M | 3.97% |
1,550,000
| – | – |
|
|
SLGC
9
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $154M | 3.82% |
+12,389,082
| New | +$154M |
|
|
VERV
10
DELISTED
Verve Therapeutics
VERV
| $143M | 3.55% |
3,038,167
| – | – |
|
11
Relay Therapeutics
RLAY
$688M
| $116M | 2.88% |
3,668,574
+293,516
| +9% | +$9.25M |
|
12
Twist Bioscience
TWST
$1.53B
| $107M | 2.66% |
1,000,000
| – | – |
|
13
Sarepta Therapeutics
SRPT
$1.82B
| $102M | 2.53% |
1,100,000
+215,000
| +24% | +$19.9M |
|
14
Codexis
CDXS
$219M
| $101M | 2.51% |
4,330,000
| – | – |
|
15
Agios Pharmaceuticals
AGIO
$2.14B
| $99.9M | 2.49% |
2,165,000
| – | – |
|
|
16
Absci
ABSI
$381M
| $89.8M | 2.23% |
+7,718,593
| New | +$89.8M |
|
17
Denali Therapeutics
DNLI
$2.07B
| $85.8M | 2.13% |
1,700,000
+90,000
| +6% | +$4.54M |
|
|
18
Ginkgo Bioworks
DNA
$593M
| $83.5M | 2.08% |
+180,070
| New | +$83.5M |
|
19
Century Therapeutics
IPSC
$43.3M
| $80.7M | 2.01% |
3,206,380
| – | – |
|
20
Revolution Medicines
RVMD
$8.7B
| $77M | 1.92% |
2,800,000
+495,000
| +21% | +$13.6M |
|
21
CareDx
CDNA
$720M
| $75.6M | 1.88% |
1,193,335
| – | – |
|
22
Tenaya Therapeutics
TNYA
$196M
| $74.1M | 1.84% |
+3,586,818
| New | +$74.1M |
|
23
Beam Therapeutics
BEAM
$2.08B
| $71.2M | 1.77% |
818,820
| – | – |
|
24
Tango Therapeutics
TNGX
$727M
| $71M | 1.77% |
+5,487,910
| New | +$71M |
|
|
DMTK
25
DELISTED
DermTech, Inc. Common Stock
DMTK
| $56M | 1.39% |
1,745,000
| – | – |
|